Key facts
- BloodGPT’s last known valuation is $11.0M (Jun 2025).
- It has raised $1.0M; the latest was Early Stage VC ($1.0M) in Jun 2025.
- Notable investors include DataMining Tech.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for BloodGPT
- ·The full record, as it builds
Funding rounds
No funding rounds for BloodGPT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BloodGPT
Developer of an AI-powered platform for diagnostic laboratories and clinics that interprets blood test results and supports clinical workflows. The company offers rapid automated analysis supported by healthcare and AI expertise, enabling laboratories and clinics to reduce workload, improve operational efficiency, and expand patient access.
- Sector
- Healthcare
- HQ
- Nicosia, Cyprus
- Founded
- 2024
- Employees
- 12
- Website
- bloodgpt.com/
- Ownership
- Privately Held (backing)
BloodGPT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BloodGPT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BloodGPT in its N-PORT filings yet. We sweep new filings monthly.